Divi's Lab share price today

Divis Laboratories Ltd's share price was ₹10,037.50 at the close on 4 November 2026. It has been rising for 24 weeks. That is 29.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹5,857 and ₹10,038, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Divis Laboratories Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 18 weeks in a row.

Over the last 11 years the share price moved +899% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹3,080 crore, +27.8% on a year earlier.

   Why: Revenue rose because custom synthesis work made up more of the business, helped by validation batches and customer programs.

   Next results: check whether commercial supply starts rather than more validation batches.

   From the earnings call on 1 Aug 2026.

2. Best operating margin in 15 quarters

   Operating margin was 41% in the June 2026 quarter, against 30% a year earlier.

   Why: Margins rose because more sales came from custom synthesis work and the company made more of its own starting materials, which helped costs.

   Next results: check whether the margin holds, because management said it depends on validation approvals and what work it sells, and would not assume the first quarter repeats.

   From the earnings call on 1 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Divi's Lab reported revenue of ₹3,080 crore, up 27.8% from ₹2,410 crore a year earlier, and a profit of ₹902 crore, up 65.5% from ₹545 crore.

Divi's Lab results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Divi's Lab's management discussed these results on a call held on 1 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Divi's Lab closed at ₹10,037.50 on 4 November 2026, up 50.8% from ₹6,656.50 a year earlier (7 November 2025) and up 92.7% over five years. Its highest weekly close since March 2016 was ₹10,037.50 on 4 November 2026.

Divi's Lab share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Divi's Lab closed at ₹10,037.50, up 2.6% on the week and up 8.5% on the month. Our read, 22 Aug 2026: Divi's April to June 2026 print demonstrated strong operational inflection with consolidated revenue rising 27.8% on a year earlier to ₹3,080 crore and profit surging 65.5% on a year earlier to ₹902 crore as custom synthesis reached 60.0% of revenue mix. The platform transition is backed by ₹2,034 crore CWIP across Unit 3 Kakinada backward integration, three dedicated custom synthesis capital spending projects (70% capitalized), and large-scale 3,000-liter solid phase peptide synthesis setups.

Earlier

• 1 Aug 2026: Divi's Lab held its results call for April to June 2026. Management guided: FY27 revenue growth: double-digit, with no point estimate or range.
• 24 Jul 2026: ex-date for a dividend of ₹30 a share.
• Results for April to June 2026: Revenue up 27.8% and profit up 65.5% on a year earlier.

Our read of the business

Divi's April to June 2026 print demonstrated strong operational inflection with consolidated revenue rising 27.8% on a year earlier to ₹3,080 crore and profit surging 65.5% on a year earlier to ₹902 crore as custom synthesis reached 60.0% of revenue mix. The platform transition is backed by ₹2,034 crore CWIP across Unit 3 Kakinada backward integration, three dedicated custom synthesis capital spending projects (70% capitalized), and large-scale 3,000-liter solid phase peptide synthesis setups.

April to June 2026: Custom synthesis mix surges to 60.0%, lifting Q1 profit by 65.5% on a year earlier to ₹902 crore.

Our read after the April to June 2026 results, written 22 August 2026.

Divi's Lab paid ₹30 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.30% at the ₹10,037.50 close on 4 November 2026. The last was a dividend of ₹30 a share, ex-date 24 July 2026.

Divi's Lab dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Divis Laboratories Ltd paid out 31% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 1 August 2026, Divi's Lab's management guided: FY27 revenue growth: double-digit, with no point estimate or range.

“We want to be the largest integrated player”Dr. Kiran S Divi, on the call for April to June 2026

What management guided

• FY27 operating margin: broadly similar to last year, but dependent on validation approvals and mix.
• Validated custom synthesis projects: commercial quantities begin after customer and regulatory qualifications; volumes and timing undisclosed.
• Validated generic products: commercial volumes expected over the next 3-6 months.
• Iodine-based contrast media: additional customer commercialisation expected in the next few months under a long-term contract.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 1 August 2026.

The changes showing up in Divi's Lab's own numbers are higher-value products and a better mix. It is too early to say whether they last.

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Checked against results and calls up to April to June 2026, 10 October 2026.

Customer inventory de-stocking or generic API price erosion accelerates faster than custom synthesis volume additions.

Each change stops working if

• : Customer inventory de-stocking or generic API price erosion accelerates faster than custom synthesis volume additions.
• : Customer clinical trial delays or regulatory agencies (US FDA / EMA) delay approvals past CY2027.
• : Intermediate qualification by global regulators takes longer than the expected 1-2 year window.
• : Innovator peptide programs face clinical trial failures or shift toward alternate enzymatic synthesis routes.

The main risks

• : West Asia logistics congestion and solvent raw material inflation create cost and transit volatility. ✓ fact
• : Unhedged foreign exchange exposure on 90% export revenue creates quarter-to-quarter P&L volatility. ✓ fact

Our read after the April to June 2026 results, written 22 August 2026.

When Divi's Lab reports July to September 2026, these are the 5 checks that show whether the story is still on course. First: Sep 2026 quarter gross margin stays above 62% and operating margin above 35% (vs 60.48% and 32.71% a year earlier) with custom synthesis at or above 56% of sales.

Divi's Lab is on 4 of our India lists: Multibagger study list, Momentum stocks, 52 week high & low and Pharma stocks.

Divis Laboratories Ltd earned ₹902 Cr of net profit in the Jun 2026 quarter, +65.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹2,568 Cr. Over 10 years profit has grown 8.6% a year on average. That is 29.3% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹545 Cr.

For the full year, FY26 profit was ₹2,568 Cr (+17.2% on the year before).

Why profit moved: revenue changed +27.8% on a year earlier and the margin moved +11.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +28.3% and revenue +16.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Divis Laboratories Ltd reported ₹3,080 Cr of revenue in the Jun 2026 quarter, +27.8% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 10.8% a year on average. The last full year, FY26, came in at ₹10,560 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹11,230 Cr.

FY26 revenue was ₹10,560 Cr, +12.8% on the year before.

Recent pace: the last four quarters grew +16.4% on average, against 10.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +16.3%, against +17.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +26.8%, against +32.2% a year (rolling over).

Divis Laboratories Ltd's operating margin was 41.0% in the Jun 2026 quarter, 11.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 28.0% and 43.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Custom synthesis mix expanded from 45% in FY25 to 56% in Q2 FY26 and 60.0% in Q1 FY27 (see C010). Because custom synthesis carries structurally higher gross margins and lower raw material consumption (31.2% in Q1 FY27 per C014), the product mix shift drives continuous EBITDA margin expansion.

Why the margin moved: operating margin changed +10.5 percentage points on the year while gross margin changed +7.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 89% of Divis Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹2,738 Cr of operating cash against ₹2,568 Cr of profit. After ₹2,640 Cr of spending on assets, ₹98.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 89% of profit came in as cash: the cash cycle got 43 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 4.0× depreciation over three years. The next section checks what that spending is building.

Divis Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 343 days in FY26, up from 300 days in FY21. It spent ₹4,949 Cr on assets over the last 3 years. Customers take 103 days to pay, and stock sits for 346 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. Three dedicated capex projects representing ~Rs 2,000 Cr outlay are nearing completion with ~70% capitalized (see C012). Physical facilities and SPPS setups are completed, with commercial shipments guided for Q3-Q4 CY2027 pending customer regulatory filings (see C018).

At FY26 sales of ₹10,560 Cr, each day of that cycle ties up about ₹28.9 Cr, so roughly ₹9,924 Cr is tied up in the business at any time.

FY26: customers took 103 days to pay and stock sat for 346 days, about 11.4 months of sales sitting as stock, for a full cycle of 343 days, longer than FY21's 300.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 346 days. Customers pay about 103 days after that. Suppliers are paid at 106 days. Together that makes the 343-day cycle.

Spending on assets: ₹4,949 Cr over the last 3 years, against ₹1,243 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹2,113 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Divis Laboratories Ltd's P/E is 89.4×, about the highest it has ever been. Its usual P/E (the middle reading) is 49.1×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹110.18.